XML 50 R32.htm IDEA: XBRL DOCUMENT
v3.6.0.2

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 12 Months Ended
--- | --- | ---
Oct. 31, 2015 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014
Significant Accounting Policies [Line Items] |  |  |  |
Common Stock, Par or Stated Value Per Share |  | $ 0.001 | $ 0.001 |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount |  | 23,532,492 | 19,778,424 | 18,850,724
Revenues, Total |  | $ 9,199 | $ 4,364 | $ 3,523
Tax Rate Assumption Related To Deferred Tax Difference Reversal |  | The Company used tax rates of 39%, 24% and 23%. |  |
Brazil [Member] |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |
Percentage of Adult Gaucher Patients Treated with Uplyso |  | 10.00% |  |
Brazil Agreement [Member] |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |
Revenues, Total |  | $ 4,000 |  |
Supply Commitment In Year 2017 |  | $ 24,300 |  |
Brazil Agreement [Member] | Subsidiaries [Member] | Fiocruz [Member] |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |
Agent Fee, Percentage Of Net Proceeds |  | 5.00% |  |
Pfizer Agreement [Member] |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |
Proceeds From Exchange For Rights To Royalties | $ 36,000 |  |  |
Pfizer Agreement [Member] | Pfizer Incorporation [Member] |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |
Collaborative Arrangement Revenues and Expenses Sharing Percentage | 60.00% |  |  |
Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |
Collaborative Arrangement Revenues and Expenses Sharing Percentage | 40.00% |  |  |
Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member] |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |
Collaborative Arrangement Revenues and Expenses Sharing Percentage | 100.00% |  |  |

X
- Definition The Company will pay a fee equal to percentage of the net proceeds generated in Brazil to its agent for services provided in assisting us complete the Brazil Agreement pursuant to an agency agreement between the agent and the Company. + References No definition available. + Details
Name: | plx_AgentFeePercentageOfNetProceeds
Namespace Prefix: | plx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangement revenues and expense sharing percentage. + References No definition available. + Details
Name: | plx_CollaborativeArrangementRevenuesExpensesSharingPercentage
Namespace Prefix: | plx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the percentage of adult Gaucher patients treated with Uplyso. + References No definition available. + Details
Name: | plx_PercentageOfAdultGaucherPatientsTreatedWithUplyso
Namespace Prefix: | plx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount received in exchange for rights to royalties. + References No definition available. + Details
Name: | plx_ProceedsFromExchangeForRightsToRoyalties
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | plx_SignificantAccountingPoliciesLineItems
Namespace Prefix: | plx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount represents an order for supply in year 2017. + References No definition available. + Details
Name: | plx_SupplyCommitmentInYear2017
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse. + References No definition available. + Details
Name: | plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal
Namespace Prefix: | plx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Antidilution -URI http://asc.fasb.org/extlink&oid=6505113 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Diluted Earnings Per Share -URI http://asc.fasb.org/extlink&oid=6510752 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Contingent Stock Agreement -URI http://asc.fasb.org/extlink&oid=6508534 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_BR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_BrazilAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=us-gaap_SubsidiariesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=plx_FiocruzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=plx_PfizerIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |